Hence, we stratified IBD patients into only two categories: (i) IBD patients treated with anti-TNFα agents and (ii) IBD patients on other treatment regimens (aminosalicylates and vedolizumab). The gene discussed is TNF; the disease is inflammatory bowel disease.